Karyopharm Therapeutics reported Q1 2026 results with an EPS of -$1.24, far below the -$0.09 forecast. Revenue rose 17% to $35.1 million, but shares fell 13.33%.
The EPS miss of 1277.78% drove the decline. The company reaffirmed its 2026 revenue guidance of $130-$150 million.
Shares closed at $7.67 after dropping from $8.85, then recovered slightly in after-hours trading.
